Documents released by BioNTech to the European Medicines Agency (EMA) reveal tens of thousands of serious adverse events and thousands of deaths among people who received the Pfizer-BioNTech mRNA COVID-19 vaccine.
The documents, dated Aug. 18, 2022, and marked “confidential,” show that cumulatively, during the clinical trials and post-marketing period up to June 18, 2022, a total of 4,964,106 adverse events were recorded. The documents included an appendix with further details about the specifics about the identified adverse events.
Among children under age 17, 189 deaths and thousands of serious adverse events were reported.
The documents present data collected between Dec. 19, 2021, and June 18, 2022 (the “PSUR #3 period”), in addition to cumulative data on adverse events and deaths that occurred among those who received the vaccine during clinical trials and during the post-marketing period, beginning December 2020 up until June 18, 2022.
During this time, Pfizer-BioNTech said it identified almost no safety signals and claimed the vaccine demonstrated over 91% “efficacy.”
“These adverse event reports are ‘off the charts,’ with myocarditis reports at over 10,000 and pericarditis reports at over 9,000.
“Historically, we know that this would be an under-ascertainment of the actual numbers. It is criminal for the EMA to keep this vaccine on the market.”
According to an analysis by commentator and author Daniel Horowitz, the percentage of adverse events classified as serious was “well above the standard for safety signals usually pegged at 15%,” and women reported adverse events at three times the rate of men.
Sixty percent of cases were reported with either “outcome unknown” or “not recovered,” suggesting many of the injuries “were not transient,” Horowitz said.
The highest number of cases occurred in the 31-50 age group, of which 92% did not have any comorbidities, making it very likely it was the vaccine causing “such widespread, sudden injury.”
There were 3,280 fatalities among vaccine recipients in the combined cumulative period including the clinical trials and post-marketing, up to July 18, 2022….